All recorded activity
- Rounds participated in
- 2
- Confirmed lead rounds
- —
2 roles undisclosed- New companies
- 2
First participation on record · 0 follow-on- Funding in participating rounds
- $440M
2 disclosed · full round size, not this investor’s share
Rounds
2 in all activityAdvanCellDevelops lead-212 targeted alpha therapies to treat cancer
Role not disclosedSonoTheraDevelops ultrasound-mediated nonviral genetic medicines
Role not disclosed